Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 9/20 | 0.38 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17224933 | 0.90 | PDE2A (0.41) | MALT1HPGDSMEN1KMT2APDE2A | |
| SCHEMBL17224958 | 0.90 | HPGDS (0.40) | HPGDSMEN1KMT2APDE2AUSP30 | |
| SCHEMBL18489080 | 0.87 | PDE2A (0.41) | PDE2A | |
| SCHEMBL17224154 | 0.86 | HPGDS (0.44) | HPGDSPDE2AUSP30 | |
| SCHEMBL17234417 | 0.85 | HPGDS (0.42) | HPGDSPDE2AUSP30 | |
| SCHEMBL12695486 | 0.85 | USP30 (0.42) | MALT1HPGDSMEN1KMT2AUSP30 | |
| SCHEMBL17224179 | 0.85 | HPGDS (0.42) | HPGDSPDE2AUSP30 | |
| SCHEMBL23608524 | 0.81 | CYP2D6 (0.35) | MALT1PDE2A | |
| SCHEMBL15942578 | 0.80 | USP30 (0.39) | MALT1HPGDSMEN1KMT2AUSP30 | |
| SCHEMBL503578 | 0.80 | USP30 (0.43) | HPGDSMEN1KMT2AUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3137459-B1 | MORPHOLIN-PYRIDINE DERIVATIVES HAVING AFFINITY TO THE TAAR1 RECEPTOR | HOFFMANN LA ROCHE (CH) | 2018-05-23 | — | — | EP | disclosed |
| US-9840501-B2 | Morpholin-pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-12-12 | — | — | US | disclosed |
| EP-3137459-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-03-08 | — | — | EP | disclosed |
| US-20170044145-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2015165835-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044145-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | OPRM1, MC2R, OPRL1 | MALT1 473/4885HPGDS 3970/4885MEN1 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.